Ada Chen

发表

AMG 580: A Novel Small Molecule Phosphodiesterase 10A (PDE10A) Positron Emission Tomography Tracer

N. Chen, E. Hu, R. Kunz, 2015, The Journal of Pharmacology and Experimental Therapeutics.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Discovery of Potent and Selective PI3Kγ Inhibitors.

N. Walker, U. Schindler, J. Powers, 2020, Journal of medicinal chemistry.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.

K. Pattabiraman, Zhulun Wang, C. Quéva, 2014, Journal of medicinal chemistry.

Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.

N. Walker, N. Sträter, D. Mandal, 2020, Journal of medicinal chemistry.

Small Molecule Therapeutics Preclinical Evaluation of AMG 925 , a FLT 3 / CDK 4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia

A. Kamb, Ji Ma, J. Medina, 2014 .

Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ).

N. Walker, U. Schindler, J. Powers, 2021, Journal of medicinal chemistry.

Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.

Y. Wang, J. Canon, J. Oliner, 2014, Journal of medicinal chemistry.

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.

Y. Wang, J. Canon, M. Peterson, 2014, Journal of medicinal chemistry.

Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.

J. Canon, J. Oliner, Xin Huang, 2014, Journal of medicinal chemistry.

Rational design and binding mode duality of MDM2-p53 inhibitors.

Xin Huang, Paul Shaffer, Steve Schneider, 2013, Journal of medicinal chemistry.

Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.

J. Canon, J. Oliner, Xin Huang, 2014, Journal of medicinal chemistry.

The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents

A. Coxon, J. Canon, J. Oliner, 2015, Molecular Cancer Therapeutics.

Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia

Alexander Kamb, John Eksterowicz, C. Quéva, 2014, Molecular Cancer Therapeutics.

Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression

G. Deng, Erik Pong, Ada Chen, 2001, Oncogene.

Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors.

N. Walker, U. Schindler, J. Powers, 2020, ACS medicinal chemistry letters.

Discovery of AB680 - A Potent and Selective Inhibitor of CD73.

N. Walker, N. Sträter, Lijuan Fu, 2020, Journal of medicinal chemistry.

Structure-based design of novel inhibitors of the MDM2-p53 interaction.

J. Canon, J. Oliner, Min Jiang, 2012, Journal of medicinal chemistry.

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity

A. Becker, J. Powers, A. Udyavar, 2022, Molecular cancer therapeutics.

Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.

Xin Huang, Paul Shaffer, Daqing Sun, 2014, ACS medicinal chemistry letters.

Discovery and Characterization of a Potent and Selective Inhibitor for Human Phosphoinositide‐3‐kinase γ

J. Powers, Lixia Jin, Xiaoning Zhao, 2020, The FASEB Journal.

Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.

N. Walker, N. Sträter, J. Powers, 2021, Journal of medicinal chemistry.

Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression.

G. Deng, Y. Kim, H. Chae, 1999, Cancer research.

Abstract 1756: Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy

U. Schindler, Lixia Jin, Ada Chen, 2018, Immunology.

AB680, a potent and selective CD73 small molecule inhibitor, reverses the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors

A. Becker, U. Schindler, J. Powers, 2018 .

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.

K. Pattabiraman, Zhulun Wang, C. Quéva, 2014, Journal of medicinal chemistry.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

258 AB308 is an anti-TIGIT antibody that enhances immune activation and anti-tumor immunity alone and in combination with other I-O therapeutic agents

F. Soriano, Xiaoning Zhao, Ada Chen, 2021, Journal for ImmunoTherapy of Cancer.

AMG 580: A Novel Small Molecule Phosphodiesterase 10A (PDE10A) Positron Emission Tomography Tracer

N. Chen, E. Hu, R. Kunz, 2015, The Journal of Pharmacology and Experimental Therapeutics.